Worldwide Point-of-Care-Ultrasound Device Industry to 2023: Surge in Geriatric Population is Driving Growth

November 24, 2020

Worldwide point-of-care-ultrasound device industry devices market is predicted to reach a value of $4,494.4 million in 2030, rising from $2,096.6 million in 2019, progressing at a 7.4% CAGR during 2020-2030.

A major factor leading to the growth of the market is the increasing number of investments that are being made in the healthcare sector by a number of countries.

As per the World Bank Group, the expenditure in the global healthcare sector rose from 8.6% in 2000 to 9.9% of the GDP in 2017. In addition to this, the rising prevalence of chronic disease and surging non-government and government initiatives for facilitating better treatment are also projected to result in the growth of healthcare expenditure, thereby driving the market. The coronavirus pandemic has, however, negatively impacted the market to some extent, and recovery is only expected to occur after the third quarter of 2020.

The European region dominated the point-of-care ultrasound devices market in 2019 due to the increasing prevalence of chronic diseases, technological advancements, and rising healthcare expenditure. As per the World Health Organization, cancer is the second major cause of morbidity and death in Europe, and account for about 1.9 million deaths every years. Therefore, the need for cost-effective and innovative diagnostic solutions, such as PoCUS devices, is increasing at a swift pace in the region.

Market Dynamics

Trends

  • Technological advancements in PoCUS devices

Drivers

  • Surge in geriatric population
  • Increasing prevalence of chronic diseases
  • Increasing awareness about benefits of portable ultrasound devices
  • Increasing healthcare expenditure
  • Impact analysis of drivers on market forecast

Restraints

  • Lack of skilled sonographers
  • Stringent regulatory norms
  • Impact analysis of restraints on market forecast

Opportunities

  • Improving healthcare infrastructure in emerging economies

Companies Mentioned

  • Esaote S.p.A.
  • Mindray Bio-Medical Electronics Co. Ltd.
  • Analogic Corporation
  • General Electric Company
  • Hitachi Ltd.
  • Siemens AG
  • Fujifilm Holdings Corporation
  • Samsung Electronics Co. Ltd.
  • Koninklijke Philips N.V.
  • Canon Inc.

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”